Chromadex Corp
Change company Symbol lookup
Select an option...
CDXC Chromadex Corp
CHMR Chimera Energy Corp
QTRX Quanterix Corp
MSEX Middlesex Water Co
EQIX Equinix Inc
PEAK Healthpeak Properties Inc
TAL TAL Education Group
CPLP Capital Product Partners LP
ONFO Onfolio Holdings Inc
CALB California BanCorp
Go

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Closing Price
$1.35
Day's Change
0.03 (2.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.45
Day's Low
1.33
Volume
(Heavy Day)
Volume:
404,988

10-day average volume:
168,325
404,988

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, October 04, 2022
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a team of scientists led by Dr...(BusinessWire)

October 03, 2022
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

ChromaDex Corp. (NASDAQ:CDXC) (the "Company"), a global bioscience company dedicated to healthy aging, today announced that it has established a joint venture through its wholly owned subsidiary ChromaDex Asia Pacific Ventures Limited (the "JV" or...(BusinessWire)

September 19, 2022
Sinopharm Xingsha to Introduce ChromaDex's Tru Niagen(R) at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen(R) at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai...(BusinessWire)

September 01, 2022
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen(R) and Tru Niagen(R) PRO into Brazil

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen(R) and Tru Niagen(R) PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key...(BusinessWire)

August 24, 2022
Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today...(PR Newswire)

August 15, 2022
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex's Intellectual Property Held Under Exclusive License From Dartmouth College

ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office's Patent Trial and Appeal Board's ("PTAB") decision to reject Thorne Research, Inc. attempt to...(BusinessWire)

August 10, 2022
ChromaDex Corporation Reports Second Quarter 2022 Financial Results

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Highlights Total net sales were $16.7 million, with $14.5 million from Tru Niagen(R), down 5% and 6% from the prior year...(BusinessWire)

August 02, 2022
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press...(BusinessWire)

July 07, 2022
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time. (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.